StockWatch
·

ESTER INDUSTRIES LTD. Q2 FY27 Results

ESTERQ2 FY27 Results
Filing
Result:Steady· Market: Flat#Turnaround#Base effect#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue443.762.7%25.3%
Total Income448.991.6%25.7%
Expenditure438.414.9%17.3%
PBT9.8758.0%157.3%
Net Profit7.8457.9%149.7%
OPM8.98%2.39pp4.95pp
NPM1.75%2.46pp6.17pp
EPS0.7559.2%53.7%
View full financials

Consolidated PAT turnaround from a loss was driven entirely by one segment (polyester chips-and-film) while specialty polymers revenue/profit collapsed ~49-53% YoY against management's own 'flat-to-single-digit' guidance, and margins/PAT compressed sharply sequentially, making this an in-line rather than standout quarter.

ESTER INDUSTRIES · Q2 FY-2027 · THE VERDICT

Recovery from Loss, Guidance into Trash

Revenue jumped 25.3% and PAT swung from a ₹15.8 Cr loss to ₹7.8 Cr profit — but specialty polymers smashed guidance, working capital ate debt reduction, and margins are razor-thin. The post-result pop faded because the street saw through the accounting optics.

12 Nov 2026 · 6 min read
Reported PAT

₹7.8 Cr

vs loss ₹15.8 Cr YoY; +149.7%

Net Profit Margin

1.8%

vs OPM 9.0%; PAT recovery masks thin margins

Specialty Polymers Q2

₹29.3 Cr

−49% YoY (was ₹57.4 Cr); breaks FY27 guidance

Films EBIT

₹34.5 Cr

8.3% margin; turnaround from ₹6.2 Cr loss YoY

The paradox: profit jumps 150%, but the quarter broke guidance

On the screen, Q2 FY-27 looks like a swing: PAT from a ₹15.8 Cr loss to ₹7.8 Cr profit, a 149.7% climb. But step back and the real story is narrower. Consolidated EBITDA margin is 10% (up 510 bps YoY), but the net margin collapse to 1.8% reveals a year-over-year base effect that's distorting optics. More importantly, this quarter formally broke the prior guidance on specialty polymers, veered wildly on working capital, and planted the question: is this recovery durable, or a rebound into a softer H2?

What holds up: films are real, specialty isn't

Management's claims vs. what holds up

Polyester films EBIT turnaround to ₹34.5 Cr vs loss ₹6.2 Cr YoY

What the numbers show

Consolidated OPM 9.0%, film segment EBIT at ₹34.5 Cr (Q2) / ₹73.6 Cr (H1) with 8.3% / 9% margins. Volume growth 13.9% YoY, revenue up 39.6% — pricing power evident.

Verdict

Supported

Specialty Polymers declining at flat-to-single-digit rates in FY27

What the numbers show

Q2 revenue ₹29.3 Cr (down 49% YoY from ₹57.4 Cr); H1 revenue ₹62 Cr (down 41% YoY from ₹105 Cr). Caused by technology/process change at largest customer; acknowledged as demand erosion, not pricing.

Verdict

Contradicted — guidance implicitly missed by >40pp

VAS products growing ~25% YoY in polyester films; targeting 35% by Q4 FY27

What the numbers show

VAS currently 26% of film volume; 25% YoY growth claimed but no prior-quarter baseline provided. Target 35% Q4, then 50–60% over 2–3 years is explicit.

Verdict

Unverified for prior guidance; Q4 target repeated but not evidenced yet

Debt repayment on track: ₹53.5 Cr in H1 toward ₹100 Cr target

What the numbers show

Gross debt rose from ₹729 Cr (Mar 26) to ₹748.8 Cr (Sept 26) due to WC buildup. H1 receivables +₹79 Cr, inventory +₹36 Cr; total WC increase ₹86.7 Cr. Net debt pressure despite repayment.

Verdict

Overstated — absolute debt rose; repayment offset by WC buildup

rPET to exceed 100% capacity by exit quarter; installed 28,000 MT

What the numbers show

Q2 rPET volume 1,437 MT; annualized ~5,700–6,000 MT ≈ 20% of 28,000 MT capacity. No utilization data provided; capacity-exceeded claim not substantiated.

Verdict

Contradicted — no evidence; claim appears withdrawn without explanation

What changed on this call

  • Specialty Polymers FY27 guidance reset: flat-to-single-digit clearly missed (−41% H1); now guiding 25% CAGR from much lower FY27 base

  • Working capital headwind unveiled: ₹86.7 Cr H1 increase due to crude/freight inflation; not pre-called in prior guidance; limiting debt reduction agenda

  • Elite JV scope formalized: 45,000 MT polyester chips, ₹1,200–1,400 Cr capex, 40–45% EBITDA target, Nike anchor customer locked, leading sports brand LOI for 15,000 MT/year

  • Specialty films VAS target elevated: 26% current → 35% Q4 FY27 → 50–60% over 2–3 years; prior explicit target not stated; mix shift expected to improve margins

The bull-bear ledger

  • Polyester films segment delivering strong EBIT recovery (₹34.5 Cr) with 8.3% margin and 39.6% revenue growth on pricing power

  • Elite JV is transformational long-term: Nike anchor pre-commits capacity; ₹1,200–1,400 Cr capex targets 40–45% EBITDA margin on 45,000 MT chips; 2028 ops timeline

  • VAS mix expansion (26% → 35% → 50–60% in 2–3 years) should provide margin resilience and reduce commodity exposure

  • Specialty Polymers crater: 49% Q2 decline, 41% H1 decline. Breaks FY27 guidance; caused by customer process change at marquee product.

  • Razor-thin net margin (1.8%) despite OPM 9.0%; PAT recovery from loss base masks underlying margin pressure

  • QoQ PAT collapsed 57.9% (Q1 ₹11.6 Cr → Q2 ₹7.8 Cr); specialty EBIT fell 33% Q1→Q2; signals H2 headwinds and cyclical softness

  • Working capital cycle not normalizing: receivables +₹79 Cr, inventory +₹36 Cr in H1; net debt rose to ₹748.8 Cr despite ₹53.5 Cr repayment

  • Film margins exposed to crude/MEG cyclicity (current 27–28 rupee spread); if crude normalizes, spread compression risk resumes

Risks, ranked by holder impact

What should concern a holder, in order

Specialty Polymers demand erosion may be structural, not cyclical

HIGH

Largest customer switched chemistry/process; if industry-wide, recovery may not materialize at promised 25% CAGR. Product concentration (50–55% of volume in 2 marquee products) amplifies risk. New product ramp is 6–8 quarters out; near-term tray remains pressured.

Working capital cycle not normalizing despite profit recovery

HIGH

Receivables +₹79 Cr, inventory +₹36 Cr in H1; net WC increase ₹86.7 Cr is offsetting debt reduction (₹53.5 Cr repaid but gross debt rose ₹19.8 Cr). If crude/freight inflation persists, this will block the ₹100 Cr FY27 debt target and impair cash conversion.

Elite JV land acquisition timeline: 'very tricky' per management, Q4 FY27 completion uncertain

MEDIUM

Described as 'very tricky' in Gujarat government-controlled park. Multiple engagement layers cited but no guarantee. If slips into FY28, project commencement (Q4 2028 ops) shifts right, delaying earnings accretion. Execution risk is real.

Film margin cyclicity returns post 8–10 quarters of overcapacity advantage

MEDIUM

Current 27–28 rupee spread is vulnerable to crude normalization. Industry overcapacity window ends in 8–10 quarters per management; after that, capacity additions and commodity pressure resume. Film EBIT margin 8.3% is healthy now but structurally cyclical.

Loop Industries financial instability may delay Elite funding

MEDIUM

Loop is dependent on private equity commitments subject to milestones. If Loop equity rounds delay or fail, Ester's 50% JV equity (₹25 Cr invested so far) may be tied up longer and project timeline slips.

Debt/leverage: gross debt ₹750 Cr, net debt ₹480 Cr above 2–2.25x EBITDA target

MEDIUM

Management acknowledged 'marginally higher than prudent'; refinancing risk is low at current spreads but leverage limits financial flexibility. If specialty decline persists, EBITDA multiple compresses and ratio deteriorates.

How the street is positioned

The post-result price action tells the story the analysts are reading. The stock popped 1.61% on day 1 from ₹87.56 (pre-result) and held momentum, reaching ₹93 by day 5 (a 6.21% total move). That pop is muted for a quarter that delivered ₹7.8 Cr profit on a ₹15.8 Cr loss year-ago (150% swing). The street, correctly, is seeing through the accounting optics to the underlying issues: specialty guidance miss of 40+ percentage points, working capital eating debt progress, and a razor-thin 1.8% net margin that signals no durable margin expansion. The post-result hold (day 5 move sustained) suggests the market has priced in a baseline recovery case but is not excited about it.

Valuation and drawdown context: Ester sits at ₹93, down 51% from its all-time high of ₹190 but up 35.67% off the 52-week low of ₹68.55. The stock trades above its 20-day SMA (₹90.14), 50-day SMA (₹90.69), and 200-day SMA (₹92.42), signaling a near-term uptrend bias. RSI of 54.5 is neutral — neither overbought nor oversold. Volume trend is normal. The drawdown from ATH remains substantial; whether this represents opportunity or a warning depends on the debate below.

Institutional positioning is notably thin. FII holdings are negligible (0.03% as of Q1 FY-27), DII holdings are 0.16%, and promoters own 62.32%. This is a promoter-locked company with minimal institutional money. No bulk or block activity is noted near the highs, suggesting no promoter trim or insider selling. The absence of FII/DII suggests the story is not attracting foreign or domestic institutional money — yet another signal that the street views this as a recovery case, not an accretion case.

The debate

What to watch next (the concrete questions that resolve the debate)

Q3 and beyond
  • 1 · Specialty Polymers bottoming and new product approvals

    Q3 H2 FY27 will show whether specialty stabilizes or continues free-fall. Management expects 'recovery from H2 onwards' as new products mature into commercial approvals. Track: (a) volume stabilization in core products, (b) new product revenue contribution (6–8 products in 6–8 quarter ramp), (c) customer count expansion (now 15–16 from 6–7). If H2 specialty revenue falls further, the 25% CAGR thesis breaks.

  • 2 · VAS mix acceleration and film margin resilience

    Polyester films VAS products are targeting 26% → 35% (Q4 FY27) → 50–60% (2–3 years). Watch: (a) does VAS reach 35% by Q4 (only 2 quarters away; current pace ~25% YoY growth), (b) what margin uplift does the mix shift deliver (management claims 200–300 bps headroom from VAS spread premium), (c) does film EBIT margin hold above 8% if crude normalizes? This will show whether the model can sustain profitability without commodity tailwinds.

  • 3 · Working capital normalization and debt trajectory

    H1 FY27 showed ₹86.7 Cr WC increase; if H2 brings normalization (flat WC), Ester can deliver closer to the ₹100 Cr full-year debt repayment target. Track: (a) receivables cycle (normalize to prior years' days sales outstanding), (b) inventory days (crude/freight cost inflation subsiding), (c) net debt trend. If WC remains elevated into Q4, the 2–2.25x EBITDA target slips further and refinancing risk rises.

  • 4 · Elite JV land acquisition and project commencement

    Management target Q4 FY27 (Oct–Dec 2026) for land acquisition completion in Gujarat; commercial ops targeted Q4 2028. Watch: (a) land position by year-end, (b) project financing tie-ups (PE commitments from Loop's side), (c) any capex or timeline adjustment. If land acquisition slips to FY28, the entire Q4 2028 ops timeline shifts right, delaying earnings accretion to 2029.

The number to track from here

Forget reported PAT (it's recovering from a loss, optics don't matter). Track H2 FY27 specialty polymers volume and new product revenue contribution. If specialty stalls or continues falling, the entire thesis — that new products will drive 25% CAGR recovery from the FY27 base — breaks. That's the single question that matters. If specialty stabilizes and new products start contributing, then Elite optionality and VAS mix upgrade become relevant. Until then, Ester is a hold-and-watch: films are real, but specialty is the make-or-break. And be honest about timelines: it's a 2–3 quarter wait to see if the specialty thesis holds or cracks further. The post-result pop didn't hold the headline momentum because the street, correctly, was unconvinced.

Ester's Q2 FY-27 is a study in optics masking substance. Headline PAT swung 150%, but the company broke guidance on its second-biggest segment, watched debt grow despite repayment efforts, and delivered a margin so thin (1.8% net) that the profit recovery looks more like a low base rebound than durable expansion. Polyester films are the strength; Elite JV is the optionality; specialty polymers is the crisis. The stock's muted post-result pop is the market's judgment — a recovery that stumbled before it started.

This is not a hold for conviction. It's a hold for the next 2–3 quarters to see if specialty polymeric products bottom and new product approvals materialize. If they do, Ester re-rates. If they don't, the stock has much further to fall from a 51% drawdown that was already steep. Watch specialty volume, not reported profit. That's where the debate resolves.

Informational and educational content only. Not investment advice.